These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 26425463)

  • 41. Impact of statins on cellular respiration and de-differentiation of myofibroblasts in human failing hearts.
    Emelyanova L; Sra A; Schmuck EG; Raval AN; Downey FX; Jahangir A; Rizvi F; Ross GR
    ESC Heart Fail; 2019 Oct; 6(5):1027-1040. PubMed ID: 31520523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
    Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statins and their role in vascular protection.
    Mason JC
    Clin Sci (Lond); 2003 Sep; 105(3):251-66. PubMed ID: 12793855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
    Martin G; Duez H; Blanquart C; Berezowski V; Poulain P; Fruchart JC; Najib-Fruchart J; Glineur C; Staels B
    J Clin Invest; 2001 Jun; 107(11):1423-32. PubMed ID: 11390424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pleiotropic effects of statins.
    Liao JK; Laufs U
    Annu Rev Pharmacol Toxicol; 2005; 45():89-118. PubMed ID: 15822172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential antitumor effects of statins (Review).
    Jakobisiak M; Golab J
    Int J Oncol; 2003 Oct; 23(4):1055-69. PubMed ID: 12963986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia.
    Bi X; Baudry M; Liu J; Yao Y; Fu L; Brucher F; Lynch G
    J Biol Chem; 2004 Nov; 279(46):48238-45. PubMed ID: 15364922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-sterol compounds that regulate cholesterogenesis. Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels.
    Bradfute DL; Simoni RD
    J Biol Chem; 1994 Mar; 269(9):6645-50. PubMed ID: 8120018
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mevalonate Cascade and its Regulation in Cholesterol Metabolism in Different Tissues in Health and Disease.
    Hashemi M; Hoshyar R; Ande SR; Chen QM; Solomon C; Zuse A; Naderi M
    Curr Mol Pharmacol; 2017; 10(1):13-26. PubMed ID: 26758949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Statins: Complex outcomes but increasingly helpful treatment options for patients.
    Mohammadkhani N; Gharbi S; Rajani HF; Farzaneh A; Mahjoob G; Hoseinsalari A; Korsching E
    Eur J Pharmacol; 2019 Nov; 863():172704. PubMed ID: 31568783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.
    Roy M; Kung HJ; Ghosh PM
    Am J Cancer Res; 2011; 1(4):542-61. PubMed ID: 21984972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rho GTPases, statins, and nitric oxide.
    Rikitake Y; Liao JK
    Circ Res; 2005 Dec; 97(12):1232-5. PubMed ID: 16339495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Direct vascular effects of HMG-CoA reductase inhibitors.
    Laufs U; Liao JK
    Trends Cardiovasc Med; 2000 May; 10(4):143-8. PubMed ID: 11239793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Statins and thrombin.
    Fenton JW; Brezniak DV; Ofosu FA; Shen GX; Jacobson JR; Garcia JG
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Apr; 5(2):115-20. PubMed ID: 15853752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells.
    Sidaway JE; Davidson RG; McTaggart F; Orton TC; Scott RC; Smith GJ; Brunskill NJ
    J Am Soc Nephrol; 2004 Sep; 15(9):2258-65. PubMed ID: 15339975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modulation of the inflammatory process by statins.
    Crisby M
    Timely Top Med Cardiovasc Dis; 2005 Mar; 9():E3. PubMed ID: 15824762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses.
    Cordle A; Landreth G
    J Neurosci; 2005 Jan; 25(2):299-307. PubMed ID: 15647473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production.
    Amuro H; Ito T; Miyamoto R; Sugimoto H; Torii Y; Son Y; Nakamichi N; Yamazaki C; Hoshino K; Kaisho T; Ozaki Y; Inaba M; Amakawa R; Fukuhara S
    Arthritis Rheum; 2010 Jul; 62(7):2073-85. PubMed ID: 20506142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.